Key Takeaways
- Recovery intact but uneven: Direct revenue grew 0.3% sequentially and 4.1% YoY, but a sharp Healthcare vertical decline from project completions masked underlying momentum in BFS and Insurance.
- BFS leads the climb back: BFS grew 1.1% sequentially, Insurance grew 2.4%, and the top 10, top 5, and next 5 accounts all grew quarter-on-quarter, supporting management's confidence in the next couple of quarters.
- Platform launches signal Gen AI ambition: Mphasis NeoZeta and NeoCrux target legacy modernization and software engineering productivity, with early live clients and a large deal already converted from the AWS Gen AI Foundry pipeline.
- Margins held steady without onetime help: EBIT margin was 15.0% despite a 0.8% drag from the Silverline acquisition, matching last quarter's 14.9% that had included onetime upsides, with operating leverage and utilization doing the work.
- What to watch next quarter: Whether Healthcare returns to sequential growth as management expects, the pace of BFS acceleration, and any signal on mortgage volumes if the 30-year rate moves closer to 6%.
Demand & Recovery Trajectory
- The bottom was December 2023: The business has now delivered two consecutive quarters of sequential growth overall and in BFS, with Q1 adding 1.0-1.3% in BFS after 2%+ last quarter.
- Healthcare masked the quarter: The Others vertical, which includes Healthcare, Manufacturing, and Retail, declined roughly 8% sequentially in INR terms. Healthcare had been one of the fastest-growing segments in FY24 but saw projects complete after a strong Q4 enrollment season, an event management called an outlier.
- Top accounts turned the corner: All three metrics, the top account, top 5, and next 5, grew quarter-on-quarter, while accounts 11-30 grew 10.2% on an LTM basis and new client acquisition revenue sustained 22% YoY growth.
- Deal ramp-up still has room: Of the $1.4 billion in deals from FY24 being monetized, not all are fully ramped. Ramp-up pace has improved from 2023 but more consumption is expected through FY25.
- Mortgage recovery is rate-dependent: Early signs of volume uptick have appeared as rates came off roughly 50 basis points, but management says it is too early to call a bottom and a meaningful pickup waits on the 30-year mortgage moving closer to 6% or 5.5%.
Nitin Rakesh: "I'm very happy to confirm to you that all the 3 metrics grew on a Q-o-Q basis, top account, top 5, next 5."
Vertical & Segment Performance
| Vertical / Segment | Trend | Commentary |
|---|---|---|
| BFS | ▲ Growth | Up 1.1% sequentially; has potential to continue leading the recovery, underpinning management's comfort on the next couple of quarters. |
| Insurance | ▲ Growth | Up 2.4% sequentially, a strong contributor within the Direct business. |
| TMT | ▲ Modest growth | Up 0.6% sequentially, driven by wins in recent quarters. |
| Logistics | ▲ Modest growth | Up 0.2% sequentially, also supported by recent wins. |
| Others (Healthcare, Manufacturing, Retail) | ▼ Declined | Down ~8% sequentially in INR, driven overwhelmingly by Healthcare project completions after a strong Q4 enrollment season. Management expects a return to sequential growth. |
| BPO | ▼ Declined | Down 2.1% sequentially as projects completed and new ones begin to ramp; grew 3.1% YoY. Stability expected ahead with early mortgage recovery signs. |
- Onsite mix has risen meaningfully: Savings Led Transformation deals and early-phase Agile Dev projects are fairly onsite-centric. Management expects the ratio to normalize as teams scale and ramp, and treats the mix as an outcome of deal type, not an objective to manage.
Nitin Rakesh: "Despite the best efforts, sometimes timing doesn't always work out in your favor, and this is one of those things."
Gen AI & Platforms
NeoZeta and NeoCrux
- NeoZeta: An industry-first modernization platform that uses Gen AI LLMs and LAMs to transform legacy applications, COBOL, Natural, legacy Java, reducing relearning time by over 50%. Already live with early beta plan engagements.
- NeoCrux: A platform to improve software engineering productivity by streamlining SDLC processes with integrated Gen AI functionalities, available as an IDE extension. In production at two live clients in the application service line.
- Platform interplay: NeoZeta e-learning agents converse with NeoCrux agents to deliver faster time-to-build for next-gen solutions.
AWS Gen AI Foundry traction
- Pipeline-to-deal conversion: One engagement taken from the Foundry converted into a large deal in Q1 FY25 for a large banking platform company. Other active solutions include KYC for a European bank, Gen AI-enabled Intelligent Document Processing for insurance clients, Live Call Analytics for a global bank, and Gen AI for modernization at large financial institutions.
Productivity and pricing
- Business cases are solidifying: Productivity of 20-30% can be built into business cases depending on what is being optimized, but realizing those gains is time-consuming and serial. Management expects slow, gradual progress and is not baking in significant gains until more foundational work is done.
- Pricing model shift: The opportunity and threat is moving away from pricing per widget toward outcome-based models, availability, or ticket reduction.
Nitin Rakesh: "This is actually an attempt to unlock the ability, to disentangle the complexity using Gen AI. So, in a way, we flipped the tables, and we are using Gen AI to relearn and extract rules."
Margins
- Sustainable 15% without onetime help: Last quarter's 14.9% margin included onetime upsides; this quarter delivered 15.0% despite a 0.8% drag from the Silverline acquisition, implying an effective 15.8% versus 15.5% two quarters back. Operating leverage, utilization improvement, and reduced exchange losses drove the underlying gain.
- Stated band holds, with flexibility: The 14.6% to 16% EBIT margin range is deliberately broader than desired at this stage of the year, preserving the option to decide quarter-by-quarter how much leverage to take back and how much to reinvest.
- Revenue growth is the biggest tailwind: Management sees an upward margin trajectory with revenue growth as the primary driver, while maintaining the philosophy of investing for growth within a narrow band.
- Headcount has been rightsized: A 7% reduction over the last two quarters, across junior and senior levels, was driven by demand needs. The pyramid is described as fairly healthy relative to the last three to four years.
Deal Wins & Pipeline
- Three large deals in Q1: One over $100 million in the BFS vertical, and one in Healthcare led by platform-based transformation using the Javelina platform.
- New-gen deal mix steady: New-gen deal wins are typically in the 75-80% range, and management expects to continue delivering at that level.
- Healthcare pipeline is building: One large deal closed this quarter, with a bunch more in the pipeline expected to close in Q2 and Q3.
- TCV guidance declined: Management said it is "very hard" to give guidance on whether TCV should see a meaningful pickup or if current levels represent a new normal.
People & the GCC Question
- Headcount reduction was demand-led: The 7% cut over two quarters was based on what is needed for demand, not a blanket exercise. Utilization is treated as an outcome of demand and supply trends, with further optimization possible depending on the pipeline.
- GCCs are not an existential threat: Management argued that if the industry's only value proposition were offshore delivery capability, there would be no business to defend. The differentiator is taking more than just offshore delivery to clients.
Nitin Rakesh: "If the only thing we are taking to the customer is offshore delivery capability, then we really don't have a business to defend as an industry. If what we are taking to them is more than just offshore delivery capability, then there is no threat to us."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | Above industry growth for FY25, gaining from tech-led account-focused strategy | FY25 |
| EBIT margin | Sustainable margin within 14.6% to 16% band, with northward bias if macro supports and revenue uplifts | FY25 |
| Healthcare recovery | Sequential growth to resume, based on deals sold and pipeline expected to close in Q2 and Q3 | Q2 onward |
| BFS growth leadership | BFS has potential to continue leading the recovery | Next couple of quarters |
| BPO stability | Stability expected ahead, with early signs of mortgage recovery but no major gains baked in yet | Near term |
| Gen AI nonlinearity | Opportunity for nonlinearity from the platform approach if change management is played right | No date |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | $410 million, +3.1% YoY constant currency, -0.1% QoQ |
| Direct revenue | 96% of overall revenue, +0.3% QoQ constant currency, +4.1% YoY |
| EBIT margin | 15.0%, Silverline acquisition costs impacted margin by 0.8%; effective margin 15.8% vs 15.5% two quarters back |
| EBIT margin target band | 14.6% to 16% |
| Reported operating profit growth | +2.8% YoY, +1.1% QoQ |
| EPS | ₹21.4, +2.8% QoQ |
| Cash flow generation | $53 million, 110% of net income |
| DSO | 68 days, +2 days QoQ, -10 days YoY |
| Large-deal TCV | $319 million in Q1, including 3 large deals, one over $100 million in BFS |
| Pipeline growth | +22% YoY, +17% QoQ |
| Top 10 accounts pipeline growth | +31% QoQ |
| BFS pipeline growth | +7% QoQ, +15% YoY |
| Non-BFS pipeline growth | +25% QoQ |
| AI-led pipeline share | One-third of pipeline |
| Proactive deal wins share | >90% of wins |
| Next-gen technologies adoption in deal wins | 84% of deal wins |
| BFS revenue growth | +1.1% QoQ overall; Direct Ex-DR +0.9% QoQ |
| Insurance revenue growth | +2.4% QoQ |
| TMT revenue growth | +0.6% QoQ |
| Logistics revenue growth | +0.2% QoQ |
| Top 10 accounts revenue | -10.1% YoY, +1.2% QoQ |
| Top 11 to 30 accounts revenue | +10.2% LTM, +3.4% QoQ |
| New client acquisition revenue growth | +22% YoY |
| U.S. Direct business revenue growth | +0.2% QoQ, +3.5% YoY |
| EMEA Direct business revenue growth | +10.4% YoY |
| Enterprise Apps revenue share and growth | ~71% of revenue, +0.6% QoQ constant currency in Direct |
| BPO segment revenue | -2.1% QoQ, +3.1% YoY |
| Headcount reduction | ~7% cut over last 2 quarters |
| EBITDA normalized level | 18.0% to 18.1% |
| FY24 deal monetization | $1.4 billion of deals from FY24, not all fully ramped |
| Global IT services spend projection | ~2.5% for the year |
| Others vertical decline | ~8% QoQ from an INR perspective, driven by Healthcare project completions |